SynCore Biotechnology Co

SynCore Biotechnology Co Capital Intensity

The Capital Intensity Ratio of SynCore Biotechnology Co (4192.TWO) as of Nov 11, 2026 is 945.54 %. In the previous year, Capital Intensity Ratio was 1,361.79 % — a change of -30.57% (lower).

Capital Intensity

945.54 %

YoY

-30.57%

Last updated:

Capital Intensity Ratio of SynCore Biotechnology Co is 2025 945.54 % . Capital Intensity Ratio of SynCore Biotechnology Co was 2024 1,361.79 % . It decreases by -30.57% lower compared to the previous year.

The SynCore Biotechnology Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
10,443.87 TWD
Jan 1, 2019
5,890.92 TWD
Jan 1, 2020
6,853.56 TWD
Jan 1, 2021
11,881.22 TWD
Jan 1, 2022
2,753.66 TWD
Jan 1, 2023
1,873.45 TWD
Jan 1, 2024
1,361.79 TWD
Jan 1, 2025
945.54 TWD
The SynCore Biotechnology Co Capital Intensity history
YEARCapital IntensityYoY
945.54 %-30.57%
1,361.79 %-27.31%
1,873.45 %-31.97%
2,753.66 %-76.82%
11,881.22 %+73.36%
6,853.56 %+16.34%
5,890.92 %-43.59%
10,443.87 %+0.55%
10,386.65 %-35.73%
16,161.39 %+143.25%
6,643.82 %-67.45%
20,413.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SynCore Biotechnology Co Stock analysis

What does SynCore Biotechnology Co do? SynCore Biotechnology Co Ltd, based in Dongshan, Yilan, Taiwan, operates in the Health Care sector with a focus on Pharmaceuticals. The company develops new drugs and integrates technology, employing 50 full-time staff. Its main product is SB03 Veregen, alongside research and development of anticancer drugs SB01 (injection and oral forms). SynCore primarily distributes its products within Taiwan. SynCore Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SynCore Biotechnology Co stock

Capital Intensity Ratio of SynCore Biotechnology Co is 945.54 % in 2025.

Capital Intensity Ratio of SynCore Biotechnology Co changed from 1,361.79 % to 945.54 %, representing a -30.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio SynCore Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's SynCore Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — SynCore Biotechnology Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — SynCore Biotechnology Co